Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2016
Reporting Period: Event-based report for June 2, 2016.
Key Financial Metrics
This filing is an event-based report and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the issuance of a sixth patent by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, the company's novel once-daily extended-release oxcarbazepine product.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (Exhibit 99.1) announcing the patent milestone. No specific financial guidance or outlook was included in this filing.
Risks and Contingencies: No specific risks or contingencies were detailed in this filing text.
Investor Verification Checklist
- Verify the scope and expiration date of the sixth patent issued for Oxtellar XR.
- Review the full text of the press release (Exhibit 99.1) for additional strategic context.
- Consult the company's most recent 10-Q or 10-K for current financial performance and liquidity status, as this 8-K contains no financial data.